Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Beam Therapeutics Inc Market Cap
From what 7 stock analysts predict, the share price for Beam Therapeutics Inc (BEAM) might increase by 62.28% in the next year. This is based on a 12-month average estimation for BEAM. Price targets go from $30.00 to $78.00. The majority of stock analysts believe BEAM is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 7 Wall Street analysts have assigned BEAM 5 buy ratings, 2 hold ratings, and 0 sell ratings. This means that analysts expect Beam Therapeutics Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on BEAM. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| eric joseph J.P. Morgan | Buy | $40.0 | upgraded | Jan 29, 2024 |
| dae gon ha Stifel Nicolaus | Buy | $66.0 | maintained | Jan 15, 2024 |
| kostas biliouris BMO Capital | Buy | $57.0 | maintained | Jan 9, 2024 |
| sami corwin William Blair | Buy | None | maintained | Jan 9, 2024 |
| yanan zhu Wells Fargo | Buy | $75.0 | maintained | Jan 8, 2024 |
| debjit chattopadhyay Guggenheim | Buy | $78.0 | maintained | Dec 21, 2023 |
| greg harrison Bank of America Securities | Hold | $35.0 | downgraded | Dec 15, 2023 |
| michael yee Jefferies | Hold | $30.0 | downgraded | Dec 8, 2023 |
| samantha semenkow Citi | Buy | $56.0 | maintained | Nov 13, 2023 |
| gena wang Barclays | Hold | $26.0 | maintained | Nov 8, 2023 |
| luca issi RBC Capital | Hold | $27.0 | maintained | Nov 8, 2023 |
| mani foroohar Leerink Partners | Hold | $19.0 | reiterated | Nov 8, 2023 |
| rick bienkowski Cantor Fitzgerald | Hold | None | downgraded | Oct 20, 2023 |
| david nierengarten Wedbush | Buy | $48.0 | maintained | Oct 19, 2023 |
| william pickering Bernstein | Hold | $35.0 | maintained | Aug 15, 2023 |
| richard law cfa Credit Suisse | Hold | $47.0 | maintained | Aug 9, 2023 |
| patrick b donnelly Citigroup | Buy | $62.0 | maintained | Mar 1, 2023 |
| raju prasad William Blair | Buy | None | initiatedcoverage | Feb 28, 2023 |
| benjamin burnett Stifel Nicolaus | Buy | $103.0 | maintained | Nov 7, 2022 |
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
When did it IPO
2020
Staff Count
439
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. John M. Evans M.B.A.
Market Cap
$2.59B
In 2023, BEAM generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that BEAM's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
DORM-USD
$82.82
MYRG-USD
$154.12
ICUI-USD
$105.19
FTDR-USD
$32.53
$25.99
GDRX-USD
$6.54
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
